EIT Evaluation of the Impact of Inhaled Nitric Oxide on Ventilation/Perfusion Mismatch in ARDS Pa… (NCT07617298) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
EIT Evaluation of the Impact of Inhaled Nitric Oxide on Ventilation/Perfusion Mismatch in ARDS Patients Receiving Noninvasive Respiratory Support
China40 participantsStarted 2026-06-30
Plain-language summary
This study aimed to quantitatively evaluate the immediate effect of inhaled nitric oxide on the ventilation / perfusion ratio in ARDS patients receiving nasal high flow oxygen therapy or noninvasive ventilation using electrical impedance tomography.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age ≥ 18 years, gender unlimited;
. Non invasive ventilation (NIV) with PEEP or CPAP ≥ 5 cmH2O or nasal high flow oxygen therapy (hfnc) with flow rate ≥ 30 l/min met the diagnostic criteria of non intubated ARDS according to the new global definition of ARDS: pao2/fio2 ≤ 300MMHG or spo2/fio2 ≤ 315 (SpO2 ≤ 97%);
. Patients with spontaneous breathing and clear consciousness can cooperate with instructions and hold breath for ≥ 8s;
. Patients with spontaneous breathing and clear consciousness can cooperate with instructions and hold breath for ≥ 8s;
Exclusion criteria
. There are signs of worsening respiratory failure requiring immediate intubation: respiratory rate \> 40 times / min with severe use of auxiliary respiratory muscles or contradictory breathing, or Paco ₂ \> 50 mmHg and pH \< 7.25;
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is using inhaled nitric oxide alongside noninvasive breathing support for ARDS — is noninvasive support even the right approach for my current severity of ARDS, or would I likely need a ventilator instead?
2The study is measuring something called the ventilation/perfusion ratio using a technique called EIT — can you explain in plain terms what that means for my lungs, and what it would actually tell the researchers about how my breathing is working?
3Since this trial is listed as 'not yet recruiting,' do you know when it's expected to open, and is it realistic to consider it given how quickly ARDS can progress?
4Inhaled nitric oxide is already used in some ARDS situations — what would I be getting in this trial that's different from what I might receive as part of standard care right now?
5Given that this study doesn't have a standard phase label, which suggests it may be more of a measurement or observational study rather than a treatment comparison, would participating actually change the care I receive, or would it mainly contribute data to research?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Oxygenation index
Timeframe: baseline, before intervention; Time point 1: After inhaling 5ppm of NO for 1 hour; Time point 2: After inhaling 10ppm of NO for 1 hour; Time point 3: After inhaling 20ppm of NO for 1 hour; Time point 4: After inhaling 40ppm of NO for 1 hour
2
Ventilation/perfusion ratio
Timeframe: baseline, before intervention; After inhaling 5ppm of NO for 1 hour; After inhaling 40ppm of NO for 1 hour
. Hemodynamic instability or the presence of refractory shock; That is, the vasoactive drugs increased by more than 30% within 6 hours, or the norepinephrine dose exceeded 0.5 μ g /kg/min;
. There are contraindications to EIT monitoring, such as thoracic implantable defibrillator / pacemaker, large area of severe skin damage on the chest, serious allergy to electrode patches, etc;
. There are contraindications to the use of iNO: such as severe left ventricular dysfunction, active bleeding, etc;
. Patients with intracranial hypertension, severe arrhythmia or digestive tract obstruction;
. Pneumothorax and massive pleural effusion were not treated;